	US 11,692,011 B2
	Hepatitis B virus-derived polypeptide and anti-viral use thereof
Bum Joon Kim, Seoul (KR); Yu Min Choi, Seoul (KR); and Hong Kim, Seoul (KR)
Assigned to SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, Seoul (KR)
Filed by SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, Seoul (KR)
Filed on Nov. 5, 2020, as Appl. No. 17/90,485.
Application 17/090,485 is a continuation in part of application No. PCT/KR2019/005302, filed on May 3, 2019.
Claims priority of application No. 10-2018-0053039 (KR), filed on May 9, 2018; and application No. 10-2018-0053040 (KR), filed on May 9, 2018.
Prior Publication US 2021/0054029 A1, Feb. 25, 2021
Int. Cl. A61K 38/16 (2006.01); A61K 38/00 (2006.01); A61P 31/14 (2006.01); A61P 31/18 (2006.01); A61P 31/20 (2006.01); C07K 14/005 (2006.01); A61K 31/708 (2006.01)

CPC C07K 14/005 (2013.01) [A61K 31/708 (2013.01); A61K 38/162 (2013.01); A61P 31/20 (2018.01); C12N 2730/10122 (2013.01); C12N 2730/10133 (2013.01)]

19 Claims

1. An isolated polypeptide comprising an end-capping modification consisting of any one amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3.